Answers are grounded in this paper and cite their sources.
In this issue of Blood, Duvic et al demonstrate that mogamulizumab, a humanized monoclonal antibody targeting the chemokine receptor CCR4, is well tolerated and has significant clinical activity (overall response rate 36.8%, median duration of response 10.4 months) in heavily pretreated patients with mycosis fungoides (MF) and Sézary syndrome (SS).
No takes yet. Share an insight, caveat, or question.
Ryan A. Wilcox (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: